These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Short-term oxycodone treatment does not affect electrogenic ion transport in isolated mucosa from the human rectosigmoid colon. Nilsson M; Brock C; Poulsen JL; Bindslev N; Hansen MB; Louring Christrup L; Drewes AM Scand J Gastroenterol; 2016; 51(5):538-47. PubMed ID: 26610166 [TBL] [Abstract][Full Text] [Related]
5. Efficacy and tolerability of oral oxycodone and oxycodone/naloxone combination in opioid-naïve cancer patients: a propensity analysis. Lazzari M; Greco MT; Marcassa C; Finocchi S; Caldarulo C; Corli O Drug Des Devel Ther; 2015; 9():5863-72. PubMed ID: 26586937 [TBL] [Abstract][Full Text] [Related]
6. Effect of a fixed-dose opioid agonist/antagonist on constipation in patients on long-term opioids for non-malignant pain unable to tolerate laxatives. Mehta V; Alaward S; Kuravinakop S; Nikolic S Pain Physician; 2014; 17(5):415-24. PubMed ID: 25247899 [TBL] [Abstract][Full Text] [Related]
7. Lubiprostone vs Senna in postoperative orthopedic surgery patients with opioid-induced constipation: a double-blind, active-comparator trial. Marciniak CM; Toledo S; Lee J; Jesselson M; Bateman J; Grover B; Tierny J World J Gastroenterol; 2014 Nov; 20(43):16323-33. PubMed ID: 25473191 [TBL] [Abstract][Full Text] [Related]
8. Bowel function after tapentadol and oxycodone immediate release (IR) treatment in patients with low back or osteoarthritis pain. Kwong WJ; Hammond G; Upmalis D; Okamoto A; Yang M; Kavanagh S Clin J Pain; 2013 Aug; 29(8):664-72. PubMed ID: 23835764 [TBL] [Abstract][Full Text] [Related]
9. Emerging therapies for patients with symptoms of opioid-induced bowel dysfunction. Leppert W Drug Des Devel Ther; 2015; 9():2215-31. PubMed ID: 25931815 [TBL] [Abstract][Full Text] [Related]
10. A randomised controlled trial with prolonged-release oral oxycodone and naloxone to prevent and reverse opioid-induced constipation. Meissner W; Leyendecker P; Mueller-Lissner S; Nadstawek J; Hopp M; Ruckes C; Wirz S; Fleischer W; Reimer K Eur J Pain; 2009 Jan; 13(1):56-64. PubMed ID: 18762438 [TBL] [Abstract][Full Text] [Related]
11. Long-term efficacy and safety of combined prolonged-release oxycodone and naloxone in the management of non-cancer chronic pain. Sandner-Kiesling A; Leyendecker P; Hopp M; Tarau L; Lejcko J; Meissner W; Sevcik P; Hakl M; Hrib R; Uhl R; Dürr H; Reimer K Int J Clin Pract; 2010 May; 64(6):763-74. PubMed ID: 20370845 [TBL] [Abstract][Full Text] [Related]
12. Definition, diagnosis and treatment strategies for opioid-induced bowel dysfunction-Recommendations of the Nordic Working Group. Drewes AM; Munkholm P; Simrén M; Breivik H; Kongsgaard UE; Hatlebakk JG; Agreus L; Friedrichsen M; Christrup LL Scand J Pain; 2016 Apr; 11():111-122. PubMed ID: 28850449 [TBL] [Abstract][Full Text] [Related]
13. Although tapentadol and oxycodone both increase colonic volume, tapentadol treatment resulted in softer stools and less constipation: a mechanistic study in healthy volunteers. Mark EB; Frøkjær JB; Hansen TM; Nedergaard RB; Drewes AM Scand J Pain; 2021 Apr; 21(2):406-414. PubMed ID: 33606931 [TBL] [Abstract][Full Text] [Related]
14. Validation of the Bowel Function Index to detect clinically meaningful changes in opioid-induced constipation. Rentz AM; Yu R; Müller-Lissner S; Leyendecker P J Med Econ; 2009; 12(4):371-83. PubMed ID: 19912069 [TBL] [Abstract][Full Text] [Related]
15. Prolonged-release oxycodone/naloxone in the treatment of neuropathic pain - results from a large observational study. Hermanns K; Junker U; Nolte T Expert Opin Pharmacother; 2012 Feb; 13(3):299-311. PubMed ID: 22224497 [TBL] [Abstract][Full Text] [Related]
16. MRI analysis of fecal volume and dryness: Validation study using an experimental oxycodone-induced constipation model. Mark EB; Bødker MB; Grønlund D; Østergaard LR; Frøkjaer JB; Drewes AM J Magn Reson Imaging; 2019 Sep; 50(3):733-745. PubMed ID: 30609164 [TBL] [Abstract][Full Text] [Related]
17. The efficacy of standard laxative use for the prevention and treatment of opioid induced constipation during oxycodone use: a small Dutch observational pilot study. Koopmans-Klein G; Wagemans MF; Wartenberg HC; Van Megen YJ; Huygen FJ Expert Rev Gastroenterol Hepatol; 2016; 10(4):547-53. PubMed ID: 26641540 [TBL] [Abstract][Full Text] [Related]
18. A randomized, placebo-controlled phase 3 trial (Study SB-767905/013) of alvimopan for opioid-induced bowel dysfunction in patients with non-cancer pain. Irving G; Pénzes J; Ramjattan B; Cousins M; Rauck R; Spierings EL; Kleoudis CS; Snidow JW; Pierce A; Wurzelmann J; Mortensen ER J Pain; 2011 Feb; 12(2):175-84. PubMed ID: 21292168 [TBL] [Abstract][Full Text] [Related]
19. Innovative pain therapy with a fixed combination of prolonged-release oxycodone/naloxone: a large observational study under conditions of daily practice. Schutter U; Grunert S; Meyer C; Schmidt T; Nolte T Curr Med Res Opin; 2010 Jun; 26(6):1377-87. PubMed ID: 20380506 [TBL] [Abstract][Full Text] [Related]
20. Prevalence and impact of constipation and bowel dysfunction induced by strong opioids: a cross-sectional survey of 520 patients with cancer pain: DYONISOS study. Abramowitz L; Béziaud N; Labreze L; Giardina V; Caussé C; Chuberre B; Allaert FA; Perrot S J Med Econ; 2013 Dec; 16(12):1423-33. PubMed ID: 24102123 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]